Suppr超能文献

人载脂蛋白A-II原在从Hep G2细胞分泌后被一种巯基蛋白酶切割。

Human proapolipoprotein A-II is cleaved following secretion from Hep G2 cells by a thiol protease.

作者信息

Gordon J I, Sims H F, Edelstein C, Scanu A M, Strauss A W

出版信息

J Biol Chem. 1984 Dec 25;259(24):15556-63.

PMID:6096378
Abstract

The two principal high-density lipoprotein apolipoproteins A-I and A-II are both initially synthesized as preproproteins. The prosegment of apo-A-I is unusual: it ends with paired glutamine residues and is removed extracellularly. The apo-A-II prosegment resembles the propeptides of prohormones and proalbumin: it ends with paired basic amino acids. We have studied the processing of proapo-A-II in a human hepatoma cell line (Hep G2) which is known to accurately and efficiently remove the prosegment from proalbumin prior to secretion. Pulse-chase experiments were performed in order to determine if the apo-A-II prosegment is removed prior to or after secretion. Apo-A-II was purified from cell lysates and media at various times during the chase and subjected to automated sequential Edman degradation. The results indicate that proteolytic processing of proapo-A-II is largely an extracellular event. These cells secrete the protease responsible for prosegment removal. The converting activity present in media is not blocked by serine protease inhibitors (phenylmethanesulfonyl fluoride, aprotinin, and furoyl saccharin) or by a metalloprotease inhibitor (o-phenanthroline). It is inhibited by the thiol protease reagents p-chloromercuribenezene-sulfonic acid and leupeptin. Prosegment removal changes the pI of the dominant apo-A-II isoform from 6.61 to 4.95. The presence of the propeptide does not prevent specific in vitro recombination of apo-A-II with high-density lipoprotein3 particles present in normolipemic serum. Extracellular processing after a single basic amino acid has been described for a variety of precursor proteins. Extracellular cleavage of the apo-A-II propeptide after paired COOH-terminal basic residues represents a novel processing pathway.

摘要

两种主要的高密度脂蛋白载脂蛋白A-I和A-II最初均以前原蛋白的形式合成。载脂蛋白A-I的前肽段不同寻常:它以成对的谷氨酰胺残基结尾,并在细胞外被去除。载脂蛋白A-II的前肽段类似于激素原和前清蛋白的前肽:它以成对的碱性氨基酸结尾。我们研究了人肝癌细胞系(Hep G2)中载脂蛋白A-II原的加工过程,已知该细胞系在分泌前能准确有效地从前清蛋白中去除前肽段。进行脉冲追踪实验以确定载脂蛋白A-II的前肽段是在分泌之前还是之后被去除。在追踪过程中的不同时间从细胞裂解物和培养基中纯化载脂蛋白A-II,并进行自动序列Edman降解。结果表明,载脂蛋白A-II原的蛋白水解加工在很大程度上是一个细胞外事件。这些细胞分泌负责去除前肽段的蛋白酶。培养基中存在的转化活性不受丝氨酸蛋白酶抑制剂(苯甲基磺酰氟、抑肽酶和呋喃甲酰糖精)或金属蛋白酶抑制剂(邻菲罗啉)的阻断。它被巯基蛋白酶试剂对氯汞苯磺酸和亮抑酶肽抑制。前肽段的去除将主要的载脂蛋白A-II同工型的pI从6.61变为4.95。前肽的存在并不妨碍载脂蛋白A-II与正常血脂血清中存在的高密度脂蛋白3颗粒进行特异性体外重组。对于多种前体蛋白,已经描述了单个碱性氨基酸后的细胞外加工过程。载脂蛋白A-II前肽在成对的COOH末端碱性残基后的细胞外切割代表了一种新的加工途径。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验